Cognate Insights

[null]

Media Inquiries

Cognate’s team is available to discuss our recent news further.

Contact

Cognate BioServices Names Tom Pamukcoglu as VP, Global Head of Quality

MEMPHIS, Tennessee, November 2, 2020 /PRNewswire/ -- Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, announced today the... Read More

J. Kelly Ganjei of Cognate announced as an Entrepreneur Of The Year® 2020 Southeast Award Finalist

Ernst & Young LLP (EY US) today announced that J. Kelly Ganjei, CEO of Cognate BioServices, Inc. was named an Entrepreneur Of The Year® 2020 Southeast Award finalist. Now in... Read More

Cognate Announces the Appointment of Two Independent Board Members

MEMPHIS, Tennessee, August 20, 2020/PRNewswire/ -- Cognate BioServices, Inc. announced today the appointments of Timothy Moore and Steven Kasok as independent non-executive... Read More

Cognate Reveals New Brand Identity with Redesigned Logo and Website

  Read More

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

MEMPHIS, Tenn., January 21, 2019 /PRNewswire/ — Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated... Read More

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Providing large scale manufacturing capacity for AZD1222 KEELE, United Kingdom, June 16, 2020 /PRNewswire/ — Cobra Biologics (Cobra), part of the Cognate BioServices family,... Read More

Cognate BioServices announces acquisition of Cobra Biologics

Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both... Read More

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry ... Read More

Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina ... Read More

Cognate BioServices, Inc. (Memphis, TN) receives Statement of Compliance to EU Good Manufacturing Practice for manufacture of Advanced Therapeutic Medicinal Products

Memphis, June 10, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today... Read More
No More Posts